The keywords used included “renal cell carcinoma”, “clear cell RCC”, “immunotherapy”, “immune checkpoint inhibitors”, “PD-1”, “PD-L1”, “CTLA-4”, “combination therapy,” “resistance,” and “ICI clinical trials”. Here, PDCD1 is linked to renal cell carcinoma.